Saturday, February 21, 2026
ISSN 2765-8767
  • Survey
  • Podcast
  • Write for Us
  • My Account
  • Log In
Daily Remedy
  • Home
  • Articles
  • Podcasts
    Debunking Myths About GLP-1 Medications

    Debunking Myths About GLP-1 Medications

    February 16, 2026
    The Future of LLMs in Healthcare

    The Future of LLMs in Healthcare

    January 26, 2026
    The Future of Healthcare Consumerism

    The Future of Healthcare Consumerism

    January 22, 2026
    Your Body, Your Health Care: A Conversation with Dr. Jeffrey Singer

    Your Body, Your Health Care: A Conversation with Dr. Jeffrey Singer

    July 1, 2025

    The cost structure of hospitals nearly doubles

    July 1, 2025
    Navigating the Medical Licensing Maze

    The Fight Against Healthcare Fraud: Dr. Rafai’s Story

    April 8, 2025
  • Surveys

    Surveys

    How Confident Are You in RFK Jr.’s Health Leadership?

    How Confident Are You in RFK Jr.’s Health Leadership?

    February 16, 2026
    AI in Healthcare Decision-Making

    AI in Healthcare Decision-Making

    February 1, 2026

    Survey Results

    Can you tell when your provider does not trust you?

    Can you tell when your provider does not trust you?

    January 18, 2026
    Do you believe national polls on health issues are accurate

    National health polls: trust in healthcare system accuracy?

    May 8, 2024
    Which health policy issues matter the most to Republican voters in the primaries?

    Which health policy issues matter the most to Republican voters in the primaries?

    May 14, 2024
    How strongly do you believe that you can tell when your provider does not trust you?

    How strongly do you believe that you can tell when your provider does not trust you?

    May 7, 2024
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Official Learner
No Result
View All Result
  • Home
  • Articles
  • Podcasts
    Debunking Myths About GLP-1 Medications

    Debunking Myths About GLP-1 Medications

    February 16, 2026
    The Future of LLMs in Healthcare

    The Future of LLMs in Healthcare

    January 26, 2026
    The Future of Healthcare Consumerism

    The Future of Healthcare Consumerism

    January 22, 2026
    Your Body, Your Health Care: A Conversation with Dr. Jeffrey Singer

    Your Body, Your Health Care: A Conversation with Dr. Jeffrey Singer

    July 1, 2025

    The cost structure of hospitals nearly doubles

    July 1, 2025
    Navigating the Medical Licensing Maze

    The Fight Against Healthcare Fraud: Dr. Rafai’s Story

    April 8, 2025
  • Surveys

    Surveys

    How Confident Are You in RFK Jr.’s Health Leadership?

    How Confident Are You in RFK Jr.’s Health Leadership?

    February 16, 2026
    AI in Healthcare Decision-Making

    AI in Healthcare Decision-Making

    February 1, 2026

    Survey Results

    Can you tell when your provider does not trust you?

    Can you tell when your provider does not trust you?

    January 18, 2026
    Do you believe national polls on health issues are accurate

    National health polls: trust in healthcare system accuracy?

    May 8, 2024
    Which health policy issues matter the most to Republican voters in the primaries?

    Which health policy issues matter the most to Republican voters in the primaries?

    May 14, 2024
    How strongly do you believe that you can tell when your provider does not trust you?

    How strongly do you believe that you can tell when your provider does not trust you?

    May 7, 2024
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Official Learner
No Result
View All Result
Daily Remedy
No Result
View All Result
Home Contrarian

Fentanyl Candy Colored Rainbows

We seek enemies, but the only enemy is within

Daily Remedy by Daily Remedy
October 10, 2022
in Contrarian
0
Fentanyl Candy Colored Rainbows

We need enemies. It’s human nature. So we create fights even when there is nothing to fight against. Pretty soon, everything becomes a binary distinction of us versus them. Sometimes it’s useful to think this way. The problems come when we apply this thinking to things that are clearly not binary.

This would be most things in healthcare, particularly those that rise to the level of national health policy, namely this incessant war on drugs we love to fight over. Our latest opponent is fentanyl, a drug that has been around since the 90s but only recently caught the media’s attention when it began appearing in batches of heroin.

Trending the term on Google reveals an interesting pattern. When policy announcements or a policy report hits mainstream media, more people search the term. It’s literally cause and effect. We saw a spike when the DEA declared fentanyl a national health crisis. We see another spike in recent days, when the DEA announced fentanyl is now packaged in different colors and flavors, almost like candy.

Most prominently, we see Google searches asking how much fentanyl can kill you or how much fentanyl is lethal, as though the lethal dose of fentanyl is some magic elixir that can turn life into death. But this is how we look at the war on drugs, as a matter of life and death, a binary construct in which we create enemies out of nothing.

In this never ending war on drugs, we fought immigrants, then physicians, and then the pharmaceutical companies. Now we are back to our original nemesis, the neighborhood drug dealer. That nefarious actor whose sole purpose is to tear the moral fabric of our neighborhoods apart, who uses fentanyl in the most horrid way possible: by disguising it as candy our kids will consume unwittingly.

It’s creating an enemy where none exists. Fostering fear where it’s not needed. Find someone to blame and make that target the enemy. When we have an enemy, we unite in defeating it. And once we unite, we win the war on drugs.

Sometimes it feels it would be worse to have no one to fight against than to lose the war on drugs. For when we have no one to blame, we have no one to fight with.

Creating this binary construct by metamorphosing the war on drugs into a battle of good versus evil, more than anything else, epitomizes the war on drugs. So of course it’s failing; how can it be anything but a failure when we cannot even understand the basic premise of drug abuse?

Drug dealers sell drugs to make money. Children have no money. So why would drug dealers waste drugs they could sell to lace candy for children that have no purchasing power?

Luckily, a few astute epidemiologists are catching on. “It’s exactly the kind of behavior from news organizations that leads to misinformation and panic and detracts from the very real public health dangers that we can and should be focused on.” Dr. Nabarun Dasgupta is quoted as saying. It’s something he would know. As the leader of the UNC Street Drug Analysis Lab, he has made a habit out of fact checking sensationalized announcements coming out of federal agencies like the DEA and CDC.

Including the one that appeared a few days ago, when the CDC reported they are seeing an alarming rise of p-fluorofentanyl, a newly discovered, more potent variant of fentanyl. Normally, raising awareness of a potent variant would be a good thing, if not for the lack of context and the abundance of yellow journalism surrounding the announcement. News outlets portrayed p-fluorofentanyl as the next killer of kids, as the secret weapon of choice for fentanyl-lacing, candy-toting neighborhood drug dealers.

However, upon closer examination, Dr. Dasgupta and his team discovered the variant appeared in combination with cocaine or methamphetamines. Which means it’s likely a contaminant, otherwise known as a lab artifact, found when studying the drugs. Not some recently unveiled variant more deadly than the ones spinning out of the latest COVID omicron mutations.

Dr. Dasgupta and his team concluded the newly discovered drug is not a new wave of fentanyl variants, but an inevitable product of making fentanyl in new ways, which may or may not be significant long term: “It’s the result of different raw materials being used to make fentanyl. We don’t know yet if it causes any specific problems.”

This is a more rational explanation for why a new variant of fentanyl appeared; and a far cry from the sensationalism that garners headlining news. But we love stories of evil actors – the mischievous immigrant, the greedy doctor, and the scheming drug dealer. In reality, much of what we see is the consequence of a poorly regulated industry with no safety standards. It’s the inevitable outcome of poorly conceived, prohibitionary policies against drug use.

But we need enemies. So we continue to create them. The funny thing about it is that the public doesn’t seem to go along with it anymore.

ShareTweet
Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Comments 0

  1. Brian Lynch says:
    3 years ago

    Astute and insightful.

    Reply
  2. Brian Lynch says:
    3 years ago

    https://www.medpagetoday.com/opinion/second-opinions/101577

    More recently, a new fentanyl myth has arisen regarding the idea of “rainbow fentanyl,” which the U.S. DEA described as “brightly-colored fentanyl” being made to “target young Americans.” The DEA did not provide any evidence to support this, and has declined to substantiate their own claim even to major media sources. It is worth noting that before the DEA director made this announcement, “rainbow fentanyl” was not even a searchable term. However, less than 90 days after this announcement there were nearly 1,400 news articles about “rainbow fentanyl” and a proposal from Congress to give the DEA almost $300 million dollars “to fight rainbow fentanyl,” something that nobody in the world of substance use and addiction had ever heard of. This is also not the only time in recent memory that the DEA has denied objective scientific facts to mischaracterize illicit fentanyl products to expand their authority.

    Reply

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Videos

This conversation focuses on debunking myths surrounding GLP-1 medications, particularly the misinformation about their association with pancreatic cancer. The speaker emphasizes the importance of understanding clinical study designs, especially the distinction between observational studies and randomized controlled trials. The discussion highlights the need for patients to critically evaluate the sources of information regarding medication side effects and to empower themselves in their healthcare decisions.

Takeaways
GLP-1 medications are not linked to pancreatic cancer.
Peer-reviewed studies debunk misinformation about GLP-1s.
Anecdotal evidence is not reliable for general conclusions.
Observational studies have limitations in generalizability.
Understanding study design is crucial for evaluating claims.
Symptoms should be discussed in the context of clinical conditions.
Not all side effects reported are relevant to every patient.
Observational studies can provide valuable insights but are context-specific.
Patients should critically assess the relevance of studies to their own experiences.
Engagement in discussions about specific studies can enhance understanding

Chapters
00:00
Debunking GLP-1 Medication Myths
02:56
Understanding Clinical Study Designs
05:54
The Role of Observational Studies in Healthcare
Debunking Myths About GLP-1 Medications
YouTube Video DM9Do_V6_sU
Subscribe

2027 Medicare Advantage & Part D Advance Notice

Clinical Reads

BIIB080 in Mild Alzheimer’s Disease: What a Phase 1b Exploratory Clinical Analysis Can—and Cannot—Tell Us

BIIB080 in Mild Alzheimer’s Disease: What a Phase 1b Exploratory Clinical Analysis Can—and Cannot—Tell Us

by Daily Remedy
February 15, 2026
0

Can lowering tau biology translate into a clinically meaningful slowing of decline in people with early symptomatic Alzheimer’s disease? That is the practical question behind BIIB080, an intrathecal antisense therapy designed to reduce production of tau protein by targeting the tau gene transcript. In a phase 1b program originally designed for safety and dosing, investigators later examined cognitive, functional, and global outcomes as exploratory endpoints. The clinical question matters because current disease-modifying options primarily target amyloid, while tau pathology tracks...

Read more

Join Our Newsletter!

Twitter Updates

Tweets by TheDailyRemedy

Popular

  • The Prevention Gap in Dementia Care

    The Prevention Gap in Dementia Care

    0 shares
    Share 0 Tweet 0
  • Healthcare in Space

    1 shares
    Share 0 Tweet 0
  • Healthcare Natural Rights

    0 shares
    Share 0 Tweet 0
  • Heat Safety Tips Every Pregnant Mother Should Know

    0 shares
    Share 0 Tweet 0
  • Tapping Into the Mind Body Connection

    0 shares
    Share 0 Tweet 0
  • 628 Followers

Daily Remedy

Daily Remedy offers the best in healthcare information and healthcare editorial content. We take pride in consistently delivering only the highest quality of insight and analysis to ensure our audience is well-informed about current healthcare topics - beyond the traditional headlines.

Daily Remedy website services, content, and products are for informational purposes only. We do not provide medical advice, diagnosis, or treatment. All rights reserved.

Important Links

  • Support Us
  • About Us
  • Contact us
  • Privacy Policy
  • Terms and Conditions

Join Our Newsletter!

  • Survey
  • Podcast
  • About Us
  • Contact us

© 2026 Daily Remedy

No Result
View All Result
  • Home
  • Articles
  • Podcasts
  • Surveys
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Official Learner

© 2026 Daily Remedy